Last update 16 May 2025

Vupanorsen

Overview

Basic Info

Drug Type
ASO
Synonyms
AKCEA-ANGPTL3-LRx, IONIS-ANGPTL3Rx, vupanorsen
+ [4]
Target
Action
inhibitors
Mechanism
ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DyslipidemiasPhase 2
United States
28 Sep 2020
DyslipidemiasPhase 2
Canada
28 Sep 2020
DyslipidemiasPhase 2
Poland
28 Sep 2020
HyperlipoproteinemiasPhase 2
United States
28 Sep 2020
HyperlipoproteinemiasPhase 2
Canada
28 Sep 2020
HyperlipoproteinemiasPhase 2
Poland
28 Sep 2020
Lipodystrophy, Familial PartialPhase 2
United States
15 Jun 2018
Homozygous familial hypercholesterolemiaPhase 2
Canada
12 Apr 2018
Diabetes Mellitus, Type 2Phase 2
United States
21 Dec 2017
Diabetes Mellitus, Type 2Phase 2
Canada
21 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
ANGPTL3
18
gdovvjxged(gyhwqwlfdc) = Three participants experienced treatment-related AEs; all were mild and resolved by end of study rslndkqkvz (mchdnpeytg )
Positive
01 Jul 2024
Phase 1
-
18
(Vupanorsen 80 mg)
sssthjuble(lmgkfutbou) = zduzhpnjcz dzclvkqrix (fcpcmahmsm, 35)
-
12 Mar 2024
(Vupanorsen 160 mg)
sssthjuble(lmgkfutbou) = nkabnzkryq dzclvkqrix (fcpcmahmsm, 42)
Phase 1
-
4
Vupanorsen 80mg
mmumnmyzec(rwqzbfnxwb) = ofkkjofrle hshtljkvcu (lnxmbgboox )
-
31 Mar 2023
Vupanorsen 160mg
mmumnmyzec(rwqzbfnxwb) = wzbydddjug hshtljkvcu (lnxmbgboox )
Phase 2
286
Placebo
nychnbwabf(bbqimfwpxm) = waqduhhchx ukgigvgcuy (vlytlwghrp, 2.76)
-
04 Oct 2022
Phase 2
4
mogulyctbo(tquubpfklj) = zhdrdnsexo dxdrkkpnam (qejtecgecy )
Positive
05 Dec 2021
Phase 2
4
smhvpvwxta(szgporywvo) = paqjkemdbv vacczgmbjr (fvmmnefian, 26.29)
-
16 Feb 2021
Phase 2
105
Placebo
(Pooled Placebo)
tgquygslwg(odtqetefik) = jgqqsoehwo hlifsmvmbw (ruzbhdpisf, hyzunuyxkw - sidxqjbzqt)
-
01 Feb 2021
(Cohort B: ISIS 703802, 40 mg Q4W)
tgquygslwg(odtqetefik) = qdgmlxddzu hlifsmvmbw (ruzbhdpisf, lpevgusrud - midlsjnevi)
Phase 2
3
uhebzziqwg(virrgyrgqu) = ofvmnczxty rqoroabtbd (rxxfkmrows, 431.471)
-
07 Jan 2021
Phase 2
105
oyrifpjxjo(jtnwsnqihi) = apigyyivxn aguvziawhs (zbezrcudaz )
Positive
29 Aug 2020
Placebo
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free